Regeneron PharmaceuticalsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Regeneron PharmaceuticalsAntibody biotech behind Eylea and Dupixent. Its GLP-1 exposure is complementary rather than competitive: the Phase 2 COURAGE trial adds trevogrumab (anti-myostatin), with or without garetosmab, on top of semaglutide to protect lean mass. At 26 weeks the combination prevented roughly half the lean-mass loss seen with semaglutide alone.
Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.
SEC filings for this company are not available at the moment.